Vicriviroc
Vicriviroc is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target C-C chemokine receptor type 5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
127 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 23 | 21 | 6 | 1 | — | 40 |
| Glioma | D005910 | EFO_0000520 | — | 8 | 10 | 1 | 1 | — | 16 |
| Astrocytoma | D001254 | EFO_0000271 | — | 5 | 7 | 2 | 1 | — | 12 |
| Oligodendroglioma | D009837 | EFO_0000631 | — | 2 | 3 | 1 | 1 | — | 6 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gliosarcoma | D018316 | — | — | 16 | 15 | 4 | — | — | 26 |
| Neoplasms | D009369 | — | C80 | 10 | 9 | 3 | — | — | 18 |
| Carcinoma | D002277 | — | C80.0 | 6 | 10 | 1 | — | — | 14 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 5 | 10 | 2 | — | 1 | 14 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 4 | 6 | 3 | — | 1 | 13 |
| Non-small-cell lung carcinoma | D002289 | — | — | 4 | 5 | 2 | — | 1 | 9 |
| Melanoma | D008545 | — | — | 4 | 6 | 1 | — | — | 9 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 3 | 3 | 1 | — | — | 6 |
| Cutaneous malignant melanoma | D000096142 | — | — | 3 | 3 | 1 | — | — | 6 |
| Adenocarcinoma | D000230 | — | — | 3 | — | 2 | — | — | 5 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 14 | 11 | — | — | — | 20 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 2 | — | — | — | 5 |
| Lymphoma | D008223 | — | C85.9 | 4 | 2 | — | — | — | 5 |
| Small cell lung carcinoma | D055752 | — | — | 1 | 5 | — | — | — | 5 |
| Central nervous system neoplasms | D016543 | — | — | 3 | 3 | — | — | — | 5 |
| Nervous system neoplasms | D009423 | — | — | 3 | 3 | — | — | — | 5 |
| Leukemia | D007938 | — | C95 | 3 | 2 | — | — | — | 4 |
| Myelodysplastic syndromes | D009190 | — | D46 | 3 | 2 | — | — | — | 4 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 3 | 2 | — | — | — | 4 |
| Myeloid leukemia | D007951 | — | C92 | 3 | 2 | — | — | — | 4 |
Show 52 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | — | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
| Anemia | D000740 | HP_0001903 | D64.9 | 1 | — | — | — | — | 1 |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | — | C92.2 | 1 | — | — | — | — | 1 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
Show 25 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pelvic organ prolapse | D056887 | EFO_0004710 | — | — | — | — | — | 1 | 1 |
| Prolapse | D011391 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vicriviroc |
| INN | vicriviroc |
| Description | (4,6-dimethyl-5-pyrimidinyl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-1-piperidinyl]methanone is a member of (trifluoromethyl)benzenes. |
| Classification | Small molecule |
| Drug class | antivirals; antivirals, chemokine receptor (CCR) antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C |
Identifiers
| PDB | — |
| CAS-ID | 306296-47-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL82301 |
| ChEBI ID | — |
| PubChem CID | 3009355 |
| DrugBank | — |
| UNII ID | TL515DW4QS (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CCR5
CCR5
Organism
Homo sapiens
Gene name
CCR5
Gene synonyms
CMKBR5
NCBI Gene ID
Protein name
C-C chemokine receptor type 5
Protein synonyms
C-C motif chemokine receptor 5 A159A, CD195, chemokine (C-C motif) receptor 5, chemokine receptor CCR5, chemokine recptor CCR5 Delta32, CHEMR13, HIV-1 fusion coreceptor, mutant C-C motif chemokine receptor
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 652 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use